BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25713899)

  • 1. Imatinib plasma levels during successful long-term treatment of metastatic-gastrointestinal stromal tumors.
    Sawaki A; Inaba K; Nomura S; Kanie H; Yamada T; Hayashi K; Okawaki M; Yamamura M; Yamaguchi Y; Hirai T; Orito E
    Hepatogastroenterology; 2014 Oct; 61(135):1984-9. PubMed ID: 25713899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib.
    Yoo C; Ryu MH; Kang BW; Yoon SK; Ryoo BY; Chang HM; Lee JL; Beck MY; Kim TW; Kang YK
    J Clin Oncol; 2010 Mar; 28(9):1554-9. PubMed ID: 20177019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
    Golabchifar AA; Rezaee S; Ghavamzadeh A; Alimoghaddam K; Dinan NM; Rouini MR
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):85-93. PubMed ID: 24817601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients.
    Eechoute K; Fransson MN; Reyners AK; de Jong FA; Sparreboom A; van der Graaf WT; Friberg LE; Schiavon G; Wiemer EA; Verweij J; Loos WJ; Mathijssen RH; De Giorgi U
    Clin Cancer Res; 2012 Oct; 18(20):5780-7. PubMed ID: 22850565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.
    Koo DH; Ryu MH; Ryoo BY; Beck MY; Na YS; Shin JG; Lee SS; Kim EY; Kang YK
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):173-82. PubMed ID: 25417047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.
    Demetri GD; Wang Y; Wehrle E; Racine A; Nikolova Z; Blanke CD; Joensuu H; von Mehren M
    J Clin Oncol; 2009 Jul; 27(19):3141-7. PubMed ID: 19451435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors.
    Yoo C; Ryu MH; Ryoo BY; Beck MY; Kang YK
    Invest New Drugs; 2013 Oct; 31(5):1367-74. PubMed ID: 23591629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease progression in some cancers may be due to low blood levels of targeted therapies.
    Tuma RS
    J Natl Cancer Inst; 2008 Jul; 100(13):912-3. PubMed ID: 18577740
    [No Abstract]   [Full Text] [Related]  

  • 9. That's the "GIST" of it: use of adjuvant imatinib after resection of a primary GI stromal tumor.
    Tap WD; Schwartz GK
    J Clin Oncol; 2014 May; 32(15):1543-6. PubMed ID: 24638004
    [No Abstract]   [Full Text] [Related]  

  • 10. [Long-term survival in a case of recurrent gastrointestinal stromal tumor treated with intermittent or low-dose imatinib].
    Kurata Y; Takaishi S; Sakuma Y; Iwasaki K; Nimura Y; Tohma T; Kagaya A; Yamamoto Y; Matsubara H
    Gan To Kagaku Ryoho; 2014 Mar; 41(3):379-82. PubMed ID: 24743288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Six months neoadjuvant imatinib improves resectability potential of gastric stromal tumors in Egyptian patients.
    Saied GM; Kensarah AM
    Int J Surg; 2010; 8(2):105-8. PubMed ID: 19944196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring of plasma imatinib concentration for the effective treatment of CML patients.
    Tsutsumi Y; Kanamori H; Yamato H; Ehira N; Miura T; Kawamura T; Obara S; Tanaka J; Asaka M; Imamura M; Masauzi N
    Leuk Res; 2004 Oct; 28(10):1117-8. PubMed ID: 15289027
    [No Abstract]   [Full Text] [Related]  

  • 13. Bioequivalence study of 400 and 100 mg imatinib film-coated tablets in healthy volunteers.
    Ostrowicz A; Mikołajczak PL; Wierzbicka M; Boguradzki P
    Acta Pol Pharm; 2014; 71(5):843-54. PubMed ID: 25362813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-dose, randomized crossover comparisons of different-strength imatinib mesylate formulations in healthy Korean male subjects.
    Kim KA; Park SJ; Kim C; Park JY
    Clin Ther; 2013 Oct; 35(10):1595-602. PubMed ID: 24060561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib.
    Tielen R; Verhoef C; van Coevorden F; Gelderblom H; Sleijfer S; Hartgrink HH; Bonenkamp JJ; van der Graaf WT; de Wilt JH
    Eur J Surg Oncol; 2013 Feb; 39(2):150-5. PubMed ID: 23084087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors.
    Delbaldo C; Chatelut E; Ré M; Deroussent A; Séronie-Vivien S; Jambu A; Berthaud P; Le Cesne A; Blay JY; Vassal G
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6073-8. PubMed ID: 17062683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical experience of imatinib mesylate for metastatic or recurrent gastrointestinal stromal tumor].
    Toyokawa T; Yamashita Y; Yamamoto A; Shimizu S; Inoue T; Kanazawa A; Tsukamoto T; Ikehara T; Nishiguchi Y
    Gan To Kagaku Ryoho; 2014 Jan; 41(1):55-8. PubMed ID: 24423952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.
    Gotta V; Widmer N; Decosterd LA; Chalandon Y; Heim D; Gregor M; Benz R; Leoncini-Franscini L; Baerlocher GM; Duchosal MA; Csajka C; Buclin T
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1307-19. PubMed ID: 25297989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use.
    Koh Y; Lee HE; Oh DY; Kim JH; Lee SH; Kim SH; Kim DW; Im SA; Kim TY; Heo DS; Kim WH; Bang YJ
    Jpn J Clin Oncol; 2012 Nov; 42(11):1020-7. PubMed ID: 22952296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours.
    Haouala A; Widmer N; Guidi M; Montemurro M; Leyvraz S; Buclin T; Eap CB; Decosterd LA; Csajka C
    Br J Clin Pharmacol; 2013 Apr; 75(4):1007-18. PubMed ID: 22891806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.